Prostate Cancer 2004;90:2317–25.
18. Attard G, Reid AH, Yap TA, et al., Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven, J Clin Oncol, 2008;26:4563–71.
19. Attard G, Reid AH, A’Hern R, et al., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer, J Clin Oncol, 2009;27:3742–8.
20. Ryan CJ, Smith MR, Fong L, et al., Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy, J Clin Oncol, 2010;28:1481–8.
21. Reid AH, Attard G, Danila DC, et al., Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate, J Clin Oncol, 2010;28:1489–95.
22. Danila DC, Morris MJ, de Bono JS, et al., Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer, J Clin Oncol, 2010;28:1496–501.
23. de Bono JS, Logothetis CJ, Molina A, et al., Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 2011;364:1995–2005.
24. Antonarakis ES, Eisenberger MA, Expanding treatment
options for metastatic prostate cancer, N Engl J Med, 2011;364:2055–8.
25. Brown JM, Corey E, Lee ZD, et al., Osteoprotegerin and RANK ligand expression in prostate cancer, Urology, 2001;57:611–6.
26. Vallet S, Smith MR, Raje N, Novel bone-targeted strategies in oncology, Clin Cancer Res, 2010;16:4084–93.
27. Fizazi K, Lipton A, Mariette X, et al., Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates, J Clin Oncol, 2009;27:1564–71.
28. Fizazi K, Carducci M, Smith M, et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized double-blind study, Lancet, 2011;377:813–22.
29. Vasaitis TS, Bruno RD, Njar VC, CYP17 inhibitors for prostate cancer therapy, J Steroid Biochem Mol Biol, 2011;125:23–31.
30. Dreicer R, Agus DB, MacVicar GR, et al., Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study, J Clin Oncol, 2010;28(Suppl.): abstract 3084.
31. Chen Y, Clegg NJ, Scher HI, Anti-androgens and androgen- depleting therapies in prostate cancer: new agents for an established target, Lancet Oncol, 2009;10:981–91.
32. Watson PA, Chen YF, Balbas MD, et al., Constitutively active androgen receptor splice variants expressed in castration-
resistant prostate cancer require full-length androgen receptor, Proc Natl Acad Sci U S A, 2010;107:16759–65.
33. Tran C, Ouk S, Clegg NJ, et al., Development of a second-generation antiandrogen for treatment of advanced prostate cancer, Science, 2009;324:787–90.
34. Scher HI, Beer TM, Higano CS, et al., Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study, Lancet, 2010;375:1437–46.
35. Foster WR, Car BD, Shi H, et al., Drug safety is a barrier to the discovery and development of new androgen receptor antagonists, Prostate, 2011;71:480–8.
36. Drake CG, Jaffee E, Pardoll DM, Mechanisms of immune evasion by tumors, Adv Immunol, 2006;90:51–81.
37. Hodi FS, Cytotoxic T-lymphocyte-associated antigen-4, Clin Cancer Res, 2007;13:5238–42.
38. Small EJ, Tchekmedyian NS, Rini BI, et al., A pilot trial of CTLA- 4 blockade with human anti-CTLA-4 in patients with hormone- refractory prostate cancer, Clin Cancer Res, 2007;13:1810–5.
39. Fong L, Kwek SS, O’Brien S, et al., Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF, Cancer Res, 2009;69:609–15.
40. Dillard T, Yedinak CG, Alumkal J, Fleseriu M, Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes, Pituitary, 2010;13:29–38.
96
EUROPEAN UROLOGICAL REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76